7.235
price down icon2.99%   -0.135
 
loading
Jade Biosciences Inc stock is traded at $7.235, with a volume of 402.58K. It is down -2.99% in the last 24 hours and up +0.00% over the past month. Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
See More
Previous Close:
$7.37
Open:
$7.09
24h Volume:
402.58K
Relative Volume:
5.30
Market Cap:
$6.01M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.54%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$7.09
$7.61
1-Week Range:
Value
$6.71
$7.6437
52-Week Range:
Value
$6.71
$13.47

Jade Biosciences Inc Stock (JBIO) Company Profile

Name
Name
Jade Biosciences Inc
Name
Phone
617-443-2400
Name
Address
930 WINTER STREET, WALTHAM
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2025-05-19
Name
Latest SEC Filings
Name
JBIO's Discussions on Twitter

Compare JBIO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
JBIO
Jade Biosciences Inc
7.235 248.70M 0 0 0 0.00
Biotechnology icon
ONC
Beigene Ltd Adr
239.87 25.61B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.92 114.83B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 41.82M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
594.22 66.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
73.51 6.36B 0 -153.72M -103.81M -2.00

Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades

Date Action Analyst Rating Change
May-07-25 Initiated Wedbush Outperform
May-05-25 Initiated Stifel Buy
May-02-25 Initiated TD Cowen Buy
Jun-18-24 Downgrade Evercore ISI Outperform → In-line
Jun-18-24 Downgrade TD Cowen Buy → Hold
Jun-18-24 Downgrade Wells Fargo Overweight → Equal Weight
Jun-17-24 Downgrade BTIG Research Buy → Neutral
Jun-17-24 Downgrade Guggenheim Buy → Neutral
Jun-17-24 Downgrade Wedbush Outperform → Neutral
Mar-25-24 Resumed Jefferies Buy
Dec-08-23 Initiated Wells Fargo Equal Weight
Mar-01-23 Initiated Guggenheim Buy
Dec-06-22 Upgrade BTIG Research Neutral → Buy
Sep-19-22 Resumed Wedbush Outperform
Aug-16-22 Downgrade BTIG Research Buy → Neutral
Feb-11-22 Initiated BTIG Research Buy
Jul-26-21 Initiated Cowen Outperform
Jul-26-21 Initiated Evercore ISI Outperform
Jul-26-21 Initiated Jefferies Buy
Jul-26-21 Initiated Wedbush Outperform
View All

Jade Biosciences Inc Stock (JBIO) Latest News

pulisher
May 20, 2025

Insider Buying: CEO Tom Frohlich Acquires Shares in Jade Biosciences Inc (JBIO) - GuruFocus

May 20, 2025
pulisher
May 14, 2025

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Jade Biosciences, Inc. Completes Reverse Merger, Launches Nasdaq Trading as JBIO, and Secures $300 Million Financing - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Jade Biosciences Secures Massive $300M Funding After Nasdaq Debut, First Clinical Trial Set for 2025 - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times

May 13, 2025
pulisher
May 05, 2025

Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

Stifel initiates Jade Biosciences stock with a Buy, $19 target By Investing.com - Investing.com India

May 05, 2025
pulisher
May 05, 2025

Stifel initiates Jade Biosciences stock with a Buy, $19 target - Investing.com

May 05, 2025
pulisher
May 03, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - marketscreener.com

May 03, 2025
pulisher
May 03, 2025

Aerovate Therapeutics, Inc. Announces Board Changes - marketscreener.com

May 03, 2025
pulisher
May 02, 2025

TD Cowen starts Jade Biosciences coverage with Buy rating By Investing.com - Investing.com Nigeria

May 02, 2025
pulisher
May 02, 2025

TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

TD Cowen starts Jade Biosciences coverage with Buy rating - Investing.com

May 02, 2025
pulisher
May 01, 2025

Aerovate Therapeutics Completes Merger with Jade Biosciences - TipRanks

May 01, 2025
pulisher
May 01, 2025

Aerovate Therapeutics Announces Range of Expected Cash Dividend - marketscreener.com

May 01, 2025
pulisher
Apr 30, 2025

RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics - QuotedData

Apr 30, 2025
pulisher
Apr 28, 2025

Jade Biosciences closes merger with Aerovate Therapeutics - Business in Vancouver

Apr 28, 2025
pulisher
Apr 28, 2025

Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously ... - Bluefield Daily Telegraph

Apr 28, 2025
pulisher
Apr 28, 2025

Jade Biosciences Completes Closing of Merger with Aerovate - GlobeNewswire

Apr 28, 2025
pulisher
Apr 25, 2025

Aerovate Therapeutics, Inc. SEC 10-Q Report - TradingView

Apr 25, 2025
pulisher
Apr 24, 2025

Aerovate (AVTE) Approves 1-for-35 Reverse Stock Split Amid Merge - GuruFocus

Apr 24, 2025
pulisher
Apr 21, 2025

Aerovate Therapeutics stockholders approve proposed merger with Jade Biosciences - TipRanks

Apr 21, 2025
pulisher
Apr 21, 2025

Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related Proposals - marketscreener.com

Apr 21, 2025
pulisher
Apr 21, 2025

Aerovate approves reverse split ahead of Jade merger - Investing.com

Apr 21, 2025
pulisher
Apr 09, 2025

Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - The Malaysian Reserve

Apr 09, 2025
pulisher
Apr 07, 2025

Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - PR Newswire

Apr 07, 2025
pulisher
Mar 27, 2025

Aerovate Therapeutics Inc. (AVTE) reports earnings - qz.com

Mar 27, 2025
pulisher
Mar 21, 2025

AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc.AVTE - Business Wire

Mar 21, 2025
pulisher
Feb 28, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE, BMTX, PFIE, ALTR on Behalf of Shareholders - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 12, 2025

Jade Biosciences to Participate in TD Cowen’s 45th Annual - GlobeNewswire

Feb 12, 2025
pulisher
Jan 23, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The MergerIPG, VTS, AVTE, MHLD - The Victoria Advocate

Jan 23, 2025
pulisher
Dec 28, 2024

AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders - Business Wire

Dec 28, 2024
pulisher
Dec 19, 2024

Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing - Business Wire

Dec 19, 2024
pulisher
Nov 13, 2024

Jade Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 13, 2024
pulisher
Nov 01, 2024

How Fairmount’s Paragon incubator steered two more companies to NASDAQ - biocentury.com

Nov 01, 2024
pulisher
Oct 31, 2024

Paragon spinout Jade casts reverse merger spell with Aerovate - Fierce Biotech

Oct 31, 2024
pulisher
Oct 29, 2024

Paragon launches another company in hot PD-1xVEGF space that goes straight to reverse merger - Endpoints News

Oct 29, 2024
pulisher
Oct 25, 2024

Chinook alums reunite following exit to Novartis; The first board appointment for Recursion’s Chris Gibson - Endpoints News

Oct 25, 2024
pulisher
Oct 24, 2024

Jade Biosciences Appoints Tom Frohlich as Chief Executive Officer and Hetal Kocinsky as Chief Medical Officer; Forms Board of Directors and Expands Financing to $95 Million - PR Newswire

Oct 24, 2024
pulisher
Aug 06, 2024

RTW backs Jade Biosciences - QuotedData

Aug 06, 2024
pulisher
Aug 05, 2024

Jade Biosciences - The Pharma Letter

Aug 05, 2024
pulisher
Aug 04, 2024

Biotech Financing Roundup: Jade Bio’s Launch, Brenig’s Debut, Confo’s Cash & More - MedCity News

Aug 04, 2024
pulisher
Aug 02, 2024

Chutes & Ladders—Takeda taps internal leader as head of US oncology business - Fierce Biotech

Aug 02, 2024
pulisher
Aug 01, 2024

Jade Biosciences Launches with $80 Million to Develop Transformative Therapies for Autoimmune Diseases - PR Newswire

Aug 01, 2024
pulisher
Jun 17, 2024

Aerovate scraps late-stage study of lung disorder drug - marketscreener.com

Jun 17, 2024
pulisher
Mar 05, 2024

symbol__ Stock Quote Price and Forecast - CNN

Mar 05, 2024
pulisher
Jun 29, 2021

AVTEAerovate Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan

Jun 29, 2021
pulisher
Jun 27, 2021

Jade Biosciences Inc Stock Price Today | NASDAQ: JBIO Live - Investing.com

Jun 27, 2021

Jade Biosciences Inc Stock (JBIO) Financials Data

There is no financial data for Jade Biosciences Inc (JBIO). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.15
price up icon 0.00%
$31.02
price down icon 0.96%
$579.77
price down icon 1.33%
$290.05
price up icon 0.45%
$4.28
price up icon 0.71%
$75.61
price up icon 0.73%
Cap:     |  Volume (24h):